(Alliance News) - Scanhell Holdings PLC said Wednesday the European Patent Office intends to grant the company's application for a European patent for its modified enolase peptides.
The patent will add to the protection of the immunotherapies developer's pipeline for the treatment of cancer. In particular, commercial exclusivity will be provided in all major European territories, including the UK, France, Germany, Switzerland, Spain and Belgium.
"The utility of the Moditope technology is increasingly being recognised as a novel and important immunotherapeutic approach in the treatment of cancer, as evidenced by the expansion of our patent portfolio and selection for presentation on the international stage," said Chief Executive Officer Cliff Holloway.
Shares in Scancell - which is heaquartered in Oxford - were up 2.5% at 5.18 pence on Wednesday in London.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)